Key Points
- Roger Jeffs, Liquidia's CEO, sold 25,000 shares on May 5 at an average price of $40.10 for $1,002,500 under a pre-arranged Rule 10b5-1 plan, leaving him with 1,398,095 shares (a 1.76% reduction) valued at about $56.06 million.
- Jeffs has executed multiple insider sales in recent weeks totaling roughly 176,316 shares, generating about $7.07 million in proceeds across those transactions.
- Liquidia (LQDA) shares opened at $42.28, trade within a one-year range of $11.85–$46.67, have a market cap of $3.76 billion, and carry an average analyst target of $43.44 with a consensus rating of "Moderate Buy."
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CEO Roger Jeffs sold 25,000 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $40.10, for a total value of $1,002,500.00. Following the completion of the sale, the chief executive officer owned 1,398,095 shares of the company's stock, valued at $56,063,609.50. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Roger Jeffs also recently made the following trade(s):
- On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
- On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.
- On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total value of $1,003,500.00.
- On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
- On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $1,256,387.28.
- On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.
- On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $1,003,000.00.
Liquidia Price Performance
Shares of NASDAQ:LQDA opened at $42.28 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $46.67. The business has a fifty day simple moving average of $36.96 and a 200 day simple moving average of $34.71. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -50.94 and a beta of 0.41.
Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. The firm's quarterly revenue was up 3072.4% on a year-over-year basis. As a group, sell-side analysts predict that Liquidia Corporation will post 1.75 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Oppenheimer increased their price objective on Liquidia from $16.00 to $19.00 and gave the stock an "underperform" rating in a report on Thursday, March 12th. BTIG Research increased their price objective on Liquidia from $49.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. Wells Fargo & Company increased their price objective on Liquidia from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Monday, March 23rd. Wall Street Zen upgraded Liquidia from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Finally, Jefferies Financial Group increased their price objective on Liquidia from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, January 13th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $43.44.
Check Out Our Latest Stock Analysis on Liquidia
Hedge Funds Weigh In On Liquidia
Several hedge funds have recently bought and sold shares of the business. Swiss National Bank increased its position in Liquidia by 1.3% during the first quarter. Swiss National Bank now owns 120,400 shares of the company's stock worth $4,544,000 after buying an additional 1,600 shares during the last quarter. Hanseatic Management Services Inc. acquired a new position in Liquidia during the first quarter worth $772,000. Archer Investment Corp acquired a new position in Liquidia during the first quarter worth $259,000. LGT Fund Management Co Ltd. acquired a new position in Liquidia during the first quarter worth $4,161,000. Finally, Valmark Advisers Inc. increased its position in Liquidia by 10.2% during the first quarter. Valmark Advisers Inc. now owns 20,546 shares of the company's stock worth $775,000 after buying an additional 1,905 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
